Walleye Capital LLC Takes $3.46 Million Position in Monopar Therapeutics Inc. $MNPR

Walleye Capital LLC bought a new position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 63,119 shares of the company’s stock, valued at approximately $3,458,000.

Other large investors have also made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in Monopar Therapeutics in the third quarter worth about $28,000. BNP Paribas Financial Markets raised its holdings in Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after purchasing an additional 349 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Monopar Therapeutics during the 4th quarter valued at about $65,000. Caitong International Asset Management Co. Ltd acquired a new position in Monopar Therapeutics during the 4th quarter valued at about $86,000. Finally, JPMorgan Chase & Co. lifted its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock valued at $69,000 after purchasing an additional 1,821 shares during the period. Institutional investors and hedge funds own 1.83% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on MNPR. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. BTIG Research increased their price objective on shares of Monopar Therapeutics from $104.00 to $117.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. HC Wainwright raised their price objective on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, July 15th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a report on Monday, March 30th. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $112.08.

Monopar Therapeutics Price Performance

Shares of MNPR stock opened at $105.70 on Friday. The stock has a market cap of $708.19 million, a PE ratio of -55.63 and a beta of 1.46. The stock has a 50-day moving average of $79.49 and a 200-day moving average of $66.36. Monopar Therapeutics Inc. has a one year low of $29.18 and a one year high of $116.64.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.41. As a group, research analysts anticipate that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.